Novavax’s recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. The company’s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). Novavax also has additional preclinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS).
- Bli medlem
- Om SwedenBIO